GLP-1 receptor agonist initiation and risk of psychiatric hospitalisation and emergency department presentation in adults with schizophrenia and type 2 diabetes in the USA: an observational cohort study using electronic health records data.
美國EHR研究思覺失調症合併糖尿病患者,GLP-1受體促效劑vs DPP-4抑制劑/SGLT2抑制劑/未用藥,追蹤精神住院與急診就診率2年,探索代謝藥物與精神症狀關聯。
Self-medication of attention-deficit/hyperactivity disorder symptoms with psychoactive substances in adults: a scoping review of how symptom-relief motives are framed and operationalised across substances.
ADHD成人自我用藥物質使用的scoping review(109篇文獻,1986-2026),映射非處方興奮劑、大麻、菸、酒等物質與ADHD症狀紓解的文獻框架,涉及診斷區辨與用藥誤用風險。
Reducing the risk of obesity, diabetes, and metabolic disorders in patients treated with antipsychotics - recommendations of the Polish Psychiatric Association Part II: diagnostics and pharmacological treatment.
波蘭精神醫學會抗精神病藥代謝併發症預防指引,建議在高風險藥物(olanzapine、clozapine)使用時考慮metformin 1,000-2,000 mg/day預防,並規定基線與6、12週、之後每12個月進行代謝監測。
CagriSema versus Semaglutide 2.4 mg monotherapy for weight management in adults with overweight or obesity, with or without type 2 diabetes: a systematic review, meta-analysis, and trial sequential analysis.
CagriSema對semaglutide體重管理效能比較(5試驗,4,746人),體重減少差7.16kg、達20%體重減輕勝算比2.10,屬內分泌代謝領域,非精神科範疇。